Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
58.85
-0.18 (-0.30%)
At close: Jun 26, 2026, 4:00 PM EDT
60.19
+1.34 (2.28%)
After-hours: Jun 26, 2026, 6:33 PM EDT
Travere Therapeutics Employees
Travere Therapeutics had 497 employees as of December 31, 2025. The number of employees increased by 112 or 29.09% compared to the previous year.
Employees
497
Change (1Y)
112
Growth (1Y)
29.09%
Revenue / Employee
$1,078,863
Profits / Employee
-$43,103
Market Cap
5.47B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 497 | 112 | 29.09% |
| Dec 31, 2024 | 385 | 5 | 1.32% |
| Dec 31, 2023 | 380 | -82 | -17.75% |
| Dec 31, 2022 | 462 | 152 | 49.03% |
| Dec 31, 2021 | 310 | 48 | 18.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Caris Life Sciences | 1,846 |
| CRISPR Therapeutics AG | 393 |
| Xenon Pharmaceuticals | 370 |
| Definium Therapeutics | 106 |
| Erasca | 103 |
| Dianthus Therapeutics | 92 |
| Oruka Therapeutics | 68 |
TVTX News
- 3 days ago - Travere Therapeutics price target raised to $65 from $56 at Guggenheim - TheFly
- 6 days ago - Travere Therapeutics price target raised to $61 from $55 at Wedbush - TheFly
- 11 days ago - Travere Therapeutics announces retirement of Chief Research Officer in 2027 - TheFly
- 11 days ago - Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027 - Business Wire
- 13 days ago - Travere Therapeutics price target raised to $70 from $62 at Citi - TheFly
- 16 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - Travere Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 24 days ago - Travere Therapeutics says Filspari generally well tolerated in Phase 3 study - TheFly